Martin Fassnacht

Martin Fassnacht at University Hospital Wurzburg is the world's foremost authority on adrenocortical carcinoma, having led the FIRM-ACT phase III trial defining mitotane-based chemotherapy regimens and co-leading the European Network for the Study of Adrenal Tumors (ENSAT). His work on mitotane pharmacokinetics, therapeutic drug monitoring, and adjuvant therapy recommendations has shaped global ACC management guidelines. He has contributed to the molecular characterization of ACC and identification of prognostic biomarkers. His comprehensive research program spanning epidemiology, pathology, systemic therapy, and molecular biology has defined the modern approach to ACC.